Articles by Ankit Singhania

Based in India, Ankit is a financial content writer and stock market analyst. He has worked for almost a decade on several financial projects related to the stock market news, fundamental research and technical analysis for several websites. He obtained his Masters Degree In finance (MS – finance) from ICFAI. Currently, he serves as a financial consultant and technical analyst at Tradersinsights.com.

PTN Stock Hits New High After the FDA Approval for Vyleesi

Jun 24 Ankit Singhania

PTN stock soared as much as 28% in early session on Monday after the United States Food and Drug Administration granted marketing approval for Palatin Technologies’ (NYSE:PTN) Vyleesi. Key Development for Amag and Palatin Technologies ... [Read]

CTRV Stock Soars 40% as FDA Issues Positive Response for CRV431

Jun 21 Ankit Singhania

CTRV stock is one of the biggest biotech stocks after ContraVir Pharmaceuticals Inc (NASDAQ:CTRV) gets a positive response from the FDA to its pre-IND meeting for developing CRV431 in NASH. Big Announcement New Jersey-based biopharmaceutical ... [Read]

EDSA Stock Soars 200% as FDA Approves Dermatitis Study

Jun 20 Ankit Singhania

EDSA stock investors are enjoying today’s ride after the FDA said that Edesa Biotech Inc (NASDAQ:EDSA) could go ahead with its clinical study of a potential new treatment for dermatitis. Big News for EDSA Stock ... [Read]

MLNT Stock Moves Up Big On FDA Boost: Baxdela sNDA

Jun 19 Ankit Singhania

MLNT stock more than tripled following Melinta Therapeutics Inc (NASDAQ:MLNT) announcing that its supplemental New Drug Application (sNDA) for Baxdela was approved by the FDA. Big Day for MLNT Stock Connecticut-based Melinta Therapeutics, which is ... [Read]

MoneyGram Stock Rockets on Ripple’s Investment News

Jun 18 Ankit Singhania

MoneyGram stock is the biggest percentage gainer on the Nasdaq after MoneyGram International Inc (NASDAQ:MGI) signed a deal with Ripple (XRP). Big Boost for MoneyGram In a development that would come as a major boost ... [Read]

NIO Stock Continues to Move Lower, Investors are Nervous

Jun 17 Ankit Singhania

The electric vehicle industry in China is in the midst of a bit of turmoil, and that has been reflected in the performance of the NIO stock over the past two weeks or so. NIO ... [Read]

ARQL Stock Jumps to 12-Year High On Encouraging ARQ 531 Data

Jun 14 Ankit Singhania

ARQL stock is having an impressive run on the market today after ArQule, Inc. (NASDAQ:ARQL) announced encouraging data from the Phase 1 trial of ARQ 531, its investigational cancer product. About Today’s Development In this regard, ... [Read]

SVRA Stock Tumbles to an All-Time Low On Molgradex’s Failure

Jun 13 Ankit Singhania

SVRA stock is taking a big hit in Thursday’s session after Savara Inc (NASDAQ:SVRA) said that Molgradex failed to meet the primary endpoint in a phase 3 study. Molgradex’s Failure Savara has had a setback ... [Read]

SYBX Stock Jumps As Synlogic Lands $80 Million from Ginkgo Bioworks

Jun 12 Ankit Singhania

SYBX stock is making solid movement after Synlogic Inc (NASDAQ:SYBX) announced an $80 million equity investment from Ginkgo Bioworks. Ginkgo’s Investment is Key for Synlogic As one of the leading biopharmaceutical companies, Synlogic Inc (SYBX) ... [Read]

CBAY Stock Hits 2-Year Low On Disappointing Drug Data News

Jun 11 Ankit Singhania

CBAY stock is under severe selling pressure after CymaBay Therapeutics Inc (NASDAQ:CBAY) reported interim data from an ongoing Phase 2b clinical trial for seladelpar. Setback for CymaBay California-based CymaBay Therapeutics has had a setback in ... [Read]